Research Paper Volume 12, Issue 17 pp 17681—17693
Long non-coding RNA Loc490 inhibits gastric cancer cell proliferation and metastasis by upregulating RNA-binding protein Quaking
- 1 Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
- 2 Basic School of Medicine, Cancer Research Institute, Central South University, Changsha 410008, Hunan, People’s Republic of China
- 3 Hunan Cancer Hospital, The Affiliated Tumor Hospital of Xiangya Medical College, Central South University, Changsha 410008, People’s Republic of China
- 4 Key Laboratory of Carcinogenesis of the Ministry of Health and Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of Education, Cancer Research Institute, Central South University, Changsha 410008, People’s Republic of China
- 5 Medical Research Center, Key Laboratory of Cancer Proteomics of the Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
- 6 Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
- 7 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
Received: February 21, 2020 Accepted: July 14, 2020 Published: September 15, 2020https://doi.org/10.18632/aging.103876
How to Cite
Copyright: © 2020 He et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Gastric cancer (GC) is one of the most common malignant tumor types worldwide. Long non-coding RNAs (lncRNAs) have important epigenetic effects, including altering the proliferation and metastasis of malignant tumors. We used gene chip technology to search for lncRNAs that were differentially expressed in GC and metastatic lymph node tissues compared with adjacent normal tissues. The lncRNA Loc490 and the RNA-binding protein Quaking (QKI) were downregulated in GC tissues and lymph node metastases compared with normal tissues, and the levels of these two genes correlated positively with one another. Loc490 expression correlated negatively with lymph node metastasis and vein/nerve invasion, while it correlated positively with overall and disease-free survival. In vitro, Loc490 post-translationally enhanced the expression of QKI and suppressed the expression of epithelial-mesenchymal transition-related molecules. Overexpression of Loc490 inhibited GC cell proliferation, invasion and metastasis and exerted strong antitumor effects in vivo, while silencing of QKI antagonized these effects. A potential binding site between Loc490 and QKI was detected through bioinformatics analysis and confirmed through RNA immunoprecipitation and mutant analyses. Our results suggest that lncRNA Loc490 inhibits GC cell proliferation and metastasis by upregulating RNA-binding protein QKI.
Gastric cancer (GC), known for its lymph node metastasis and high morbidity and mortality, is one of the most common malignant tumors in Southeast Asia, Central/Eastern Europe and Africa. Although the incidence and mortality of GC have declined gradually over the years, GC is still the second leading cause of cancer-related death worldwide due to the lack of early-stage diagnostic methods and effective treatments. In 2015, there were 679,100 new GC cases and 498,000 GC-related deaths in China, making GC second only to lung cancer .
The size, infiltration depth, lymph node metastasis and distant metastasis rates of GC are important prognostic indicators. Various mechanisms may contribute to the malignant proliferation and metastasis of GC cells, including the epithelial-mesenchymal transition (EMT). During the EMT, epithelial cells acquire mesenchymal characteristics such as extracellular matrix degradation, increased activity and anti-apoptotic properties, thereby becoming more malignant [2–4]. Thus, elucidating the regulatory mechanisms of the EMT is vital for preventing and treating malignant tumors.
Long non-coding RNAs (lncRNAs) are non-coding RNAs with > 200 base pairs, which were once thought to be transcriptional noise, but are now known to be key regulators of epigenetics, the cell cycle and differentiation . Abnormal expression of various lncRNAs contributes to the development of malignant tumors [6, 7], including GC. For instance, lncRNA HOTAIR promotes GC cell invasion, migration and chemotherapy resistance by activating the phosphoinositide 3-kinase/AKT/multidrug resistance-associate protein 1 and Wnt/β-catenin pathways and upregulating Human epidermal growth factor receptor 2 [8–10]. LncRNA H19, the earliest discovered imprinted gene, is upregulated in GC tissues and enhances the malignant proliferation of GC via a novel pathway H19/miR-675/RUNX1 but also directly up-regulate the expression of ISM1 and indirectly inhibit the expression of CALN1 through miR-675, which can potentially be contributes to the malignant biological behaviour of GC cells [11–13]. LncRNA metastasis-associated lung adenocarcinoma transcript 1 enhances EMT-induced GC cell invasion and migration . LncRNA maternally expressed gene 3 is downregulated in GC tissues and can suppress GC proliferation and metastasis by upregulating P53 and downregulating the transcription factor E2F3 [15–16].
The above studies have indicated that lncRNAs are involved in the progression of GC; however, the functions of the majority of lncRNAs have not been fully elucidated. In the present study, we identified an additional lncRNA that was differentially expressed in GC tissues and explored its mechanism of action.
Expression of Loc490 and QKI in GC-associated tissues
We used an Agilent Human LncRNA gene chip to compare the lncRNA and mRNA levels in GC and metastatic lymph node tissues with those in normal tissues adjacent to the GC. In total, 2669 lncRNAs were upregulated and 3506 lncRNAs were downregulated (fold change > 2.0) in GC tissues and lymph node metastasis tissues compared with adjacent normal tissues. To determine the correlation of aberrantly expressed lncRNAs with the metastatic phenotype in GC, we compared the expression profiles of GC samples, adjacent normal tissues and lymph node metastases after ensuring that the RNA was not degraded (Figure 1A and 1B). Upon repeating the analysis and narrowing the results by gene expression consistency, we found that 1707 lncRNAs were differentially expressed in these samples, and there were more upregulated lncRNAs (1025) than downregulated lncRNAs (682) in the cancerous tissues. The consistently abnormally expressed lncRNAs correlated with lymph node metastasis, distant metastasis and advanced tumor-node-metastasis (TNM) stages.
Figure 1. Low expression of Loc490 in GC and lymph node metastasis tissue. (A) RNA quality testing (C: GC tissue; L: lymph node metastasis tissue; N: normal tissue adjacent to GC); (B) Screening for differentially expressed lncRNAs using Agilent Human LncRNA chip technology in normal tissues adjacent to GC, primary GC tissues and lymph node metastasis tissues; (C) Loc490 expression was significantly lower in lymph node metastases than in normal tissues adjacent to GC and in primary GC tissue (the other selected genes are shown in the article); (D) qRT-PCR results demonstrating Loc490 expression in 28 normal tissues adjacent to GC, primary GC tissues and lymph node metastasis tissues; (E) Expression of QKI mRNA in 28 normal tissues adjacent to GC, primary GC tissues and lymph node metastases; (F) Correlation analysis demonstrating that Loc490 expression was significantly positively correlated with QKI mRNA expression. Data represent the mean and SD from three experiments. **p < 0.01, ***p < 0.001.
To validate the microarray data, we used a Pearson algorithm to calculate the correlation between mRNA and lncRNA levels. Based on their fold-changes, the nine the most differentially expressed lncRNAs (upregulated lncRNAs: CD4, PRPF40B, SRGN, FGD2, C17orf46 and ZBTB; downregulated lncRNAs: LOC101927490, LOC101929897 and C8orf49) were selected from the aberrantly expressed lncRNAs. We also selected the five most differentially expressed mRNAs (upregulated mRNAs: TGFβ-1 and FXYD5; downregulated mRNAs: MUC5AC, MUC6 and TMEM97). Then, we validated the differential expression of the selected lncRNAs in 83 clinical tissue samples using quantitative real-time PCR (qRT-PCR) (Figure 1C). Despite great variability due to the small sample size, the fold-changes in all the lncRNAs in the 83 clinical samples were similar to those measured on the microarray. LOC101927490 (Loc490) was stably downregulated in GC tissues and metastatic lymph nodes compared with adjacent normal tissues. The average levels of all the selected lncRNAs differed between tissues with and without lymph node metastases (p < 0.01 or p < 0.05 for specific lncRNAs). These results revealed the consistency between the qRT-PCR data and the microarray data.
Next, we performed a bioinformatics analysis to identify Loc490-binding proteins. The RNA-binding protein Quaking (QKI) was retrieved. QRT-PCR analysis of the collected clinical samples revealed that the expression pattern of QKI was consistent with that of Loc490 (Figure 1D and 1E). This finding was confirmed in a correlation analysis (Figure 1F).
Correlation between Loc490 expression and patients’ clinical pathological data and prognoses
Next, we examined the correlation between lncRNA Loc490 expression and patients’ clinical pathological features. As shown in Table 1, there were no differences in age, gender, histologic grade or carcinoembryonic antigen levels according to Loc490 expression. However, low expression of Loc490 was associated with a pathological metastasis status and distal lymph node metastasis (p < 0.05) and correlated with TNM staging (although the p value was not statistically significant), suggesting that Loc490 expression probably correlated negatively with metastasis status and positively with overall survival.
Table 1. The expression of Loc490 and clinical parameters of patients with GC (n=83).
|Characteristics||Loc490 Expression Levels||P value|
|Low (n,%)||High (n,%)|
|Male||37 (44.6%)||23 (27.7%)||0.57|
|Female||14 (16.9%)||9 (10.8%)|
|Age (years)||66.9 ± 11.3||64.5 ± 11.4||0.463|
|Well, moderate||11 (13.2%)||13 (15.7%)||0.083|
|Poor, signet||40 (48.2%)||19 (22.9%)|
|m, sm, mp||10 (12%)||9 (10.8%)||0.426|
|ss, se, si||41 (49.4%)||23 (27.7%)|
|Lymph node invasion|
|Yes||36 (43.4%)||18 (21.7%)||0.238|
|No||15 (18.1%)||14 (16.9%)|
|Yes||39 (47%)||17 (20.5%)||0.033*|
|No||12 (14.5%)||15 (18.1%)|
|Yes||35 (42.2%)||13 (15.7%)||0.022*|
|No||16 (19.3%)||19 (22.9%)|
|Lymph node metastasis|
|Yes||24 (28.9%)||7 (8.4%)||0.035*|
|No||27 (32.5%)||25 (30.1%)|
|I–II||12 (14.5%)||14 (16.9%)||0.088|
|III–IV||39 (47%)||18 (21.7%)|
|≤2.5||18 (21.7%)||15 (18.1%)||0.359|
|>2.5||33 (39.8%)||17 (20.5%)|
Univariate and multivariate analyses were performed to determine which clinical variables were associated with the survival of GC patients. Although Loc490 expression was significantly associated with survival in the univariate analysis, it did not independently predict overall survival in the multivariate analysis. On the other hand, distal metastasis coupled with the TNM stage was strongly associated with overall survival in the multivariate Cox proportional hazards model. A Kaplan-Meier survival analysis and log-rank test were also used to evaluate the effects of Loc490 expression and clinical pathological characteristics on overall survival. The results indicated that patients with low Loc490 levels had significantly worse overall survival and disease-free survival than patients with high Loc490 levels (Figure 2).
Loc490 expression in GC cell lines and effects of Loc490 overexpression/knockdown
We next used qRT-PCR to assess Loc490 expression in different GC cell lines (AGS, SGC-7901, BGC-823 and MGC-803) and normal gastric epithelial cells (GES-1). Loc490 levels were lower in the GC cell lines than in GES-1 cells (Figure 3A). Among the GC cell lines, SGC-7901 cells exhibited the lowest Loc490 levels, while AGS cells exhibited the highest levels. Thus, to determine the significance of Loc490 downregulation in GC tissues, we constructed Loc490 overexpression and interference vector plasmids and transfected them into SGC-7901 and AGS cells, respectively. QRT-PCR analysis confirmed the overexpression and knockdown of Loc490 in the transfected GC cell lines (Figure 3B and 3C).
Figure 3. Low expression of Loc490 confers GC cell proliferative advantage. (A). Expression of Loc490 in a normal gastric epithelial cell line and GC cell lines; (B, C) Overexpression/knockdown of Loc490 in GC cell lines; (D, H) Clone formation results in Loc490-overexpressing/knockdown cell lines; (E, I) MTS assay results; (F, J) Invasion assay results and quantification; (G, K) Migration assay results and quantification. Scale bars: 100 μm. Data represent the mean and SD from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
Next, we performed MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), Transwell and clone formation assays to investigate the effects of overexpressing or silencing Loc490 on the invasion and metastasis of GC cell lines, using an empty plasmid cell line as the control group (Figure 3D–3H). The number of migrating and invading GC cells was significantly lower in the Loc490 overexpression group than in the control group, while it was significantly greater in the Loc490 knockdown group than in the control group. Thus, the expression of lncRNA Loc490 correlated inversely with the invasion and metastasis abilities of GC cells, consistent with the results of the previous experiments.
Effects of Loc490 on QKI, N-cadherin, E-cadherin, MMP-9 and Vimentin expression
QKI mRNA levels were found to correlate with Loc490 levels in GC tissues. To further investigate the mechanism whereby Loc490 overexpression inhibited GC invasion and metastasis, we used qRT-PCR and Western blotting to detect QKI and invasion/metastasis-associated proteins in Loc490-overexpressing and - knockdown cell lines (Figure 4A–4D). N-cadherin, matrix metalloproteinase 9 (MMP-9) and Vimentin were downregulated in Loc490-oxerexpressing SGC-7901 cells, but were upregulated in Loc490-knockdown AGS cells. Interestingly, QKI and E-cadherin were upregulated in Loc490-overexpressing SGC-7901 cells, but were downregulated in Loc490-knockdown AGS cells. The mRNA and protein levels of N-cadherin and E-cadherin were consistent with one another in both cell types. These results suggested that the downregulation of Loc490 promoted the invasion and migration of GC cell lines by inducing invasion/metastasis-related proteins such as MMP-9 and Vimentin, while the overexpression of Loc490 inhibited tumor invasion by inducing QKI and E-cadherin.
Figure 4. The expression of Loc490 changes the expression of EMT-related proteins. (A, C) Changes in QKI, N-cadherin, E-cadherin, MMP-9 and Vimentin mRNA levels in Loc490-overexpressing cell lines; (B) Changes in QKI, N-cadherin, E-cadherin, MMP-9 and Vimentin protein levels in Loc490-overexpressing cell lines; (D) Changes in QKI, N-cadherin, E-cadherin, MMP-9 and Vimentin protein levels in Loc490-knockdown cell lines; (E) RNA immunoprecipitation assay to detect Loc490 expression. Data represent the mean and SD from three experiments. *p < 0.05, **p < 0.01.
Binding of Loc490 to QKI suppresses GC invasion and metastasis in vitro and in vivo
To explore whether RNA-binding protein QKI could bind directly to Loc490, we performed a bioinformatics analysis, which revealed two potential binding sites on Loc490: nucleotides 760-778 UCCUAACCUG and 860-869 UAAUAACACA. Then, we mutated these two binding sites on Loc490 and used RNA-binding protein immunoprecipitation antibodies to detect the binding between the lncRNA and the protein. The binding of Loc490 to QKI decreased after the two binding sites on Loc490 were mutated, suggesting that QKI binds directly to these two sites (Figure 5A). Thus, Loc490 likely suppressed GC cell invasion and migration by binding to QKI, rather than performing various functions in parallel (Supplementary Figure 1).
Figure 5. Inhibit QKI expression by interfering Loc490 expression in GC cells and affect the biological behavior. (A) Loc490 mutations at two binding sites; (B, C) Expression of Loc490 and QKI; (D, E). Invasion and proliferation assay results in SGC-7901 cells; (F) Tumor volume in each group of nude mice; (G) Representative tumors from each group are shown after three weeks (time calculated one week after the subcutaneous inoculation of the nude mice). (A: Vector + siControl, B: Loc490 + siControl, C: Loc490 + siQKI). Scale bars: 100 μm. Data represent the mean and SD from three experiments. **p < 0.01, ***p < 0.001.
To confirm that the effects of Loc490 in GC cells depended on the induction of QKI, we divided SGC-7901 cells into three groups for small interfering RNA (siRNA) experiments: Vector + control siRNA (siControl), Loc490 + siControl, and Loc490 + QKI siRNA (siQKI). QRT-PCR and Western blotting demonstrated that the siRNA effectively inhibited QKI expression (Figure 5B and 5C). Then, the invasion and metastasis abilities of the transfected cells were detected with MTS and Transwell assays (Figure 5D and 5E). In addition, nude mice were subcutaneously inoculated with the transfected SGC-7901 cells, and their tumor volumes were measured (Figure 5F and 5G). The viability and invasiveness of the cells and the tumor volumes of the mice were significantly lower in the Loc490 + siControl group than in the Vector + siControl group and the Loc490 + siQKI group. These results indicated that the invasion and metastasis abilities of GC cells decreased when Loc490 was overexpressed, consistent with our previous experimental results (Figure 3). In summary, we confirmed that the direct binding of lncRNA Loc490 to RNA-binding protein QKI inhibited the proliferation and metastasis of GC in vitro and in vivo.
QKI, which belongs to the Signal Transduction and Activation of RNA family of KH domain-containing RNA-binding proteins, participates in pre-mRNA splicing, microRNA regulation and circular RNA formation . Many studies have revealed that QKI is a crucial tumor suppressor that prevents the initiation and progression of various malignancies. For instance, lower QKI expression in lung cancer was associated with a poorer prognosis, while QKI overexpression inhibited the malignant proliferation of lung cancer cells in vivo and in vitro by preventing Notch signaling pathway activation . QKI expression was reduced in prostate cancer tissue and was associated with cell differentiation, the TNM stage and the overall survival rate. Accordingly, QKI overexpression inhibited prostate cancer cell proliferation and tumorigenesis in vitro and in vivo . QKI was also downregulated in colorectal cancer tissues and cell lines, and was reported to inhibit cell cycle progression and invasion in colorectal cancer by negatively regulating microRNA-155 . Low QKI expression was detected in oral cancer tissues and oral cancer stem cells, but cell and mouse experiments indicated that QKI could inhibit cancer stem cell sphere formation by binding to and inhibiting the 3' untranslated region of SOX2 . Lipopolysaccharide reduced QKI expression in a microRNA-155-dependent manner during leukemogenesis, whereas QKI overexpression impaired the lipopolysaccharide-induced phosphorylation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase . The downregulation of QKI due to promoter hypermethylation was detected in GC tissues and correlated with a poorer differentiation status, greater invasion depth, gastric lymph node metastasis, distant metastasis, advanced TNM stage and poorer patient survival. However, QKI overexpression reduced the proliferation of GC cell lines in vitro .
Considering the extensive biological functions of lncRNAs and their importance in malignant tumors [24–26], we used a high-throughput sequencing technique to identify lncRNAs associated with GC metastasis. LncRNA Loc490 downregulation was found to be associated with GC metastasis, and a bioinformatics website (http://rbpdb.ccbr.utoronto.ca/) detected two potential binding sites (UCCUAACCUG and UAAUAACACA) between Loc490 and the anti-oncogene QKI. Furthermore, we assessed the expression of Loc490 and QKI and their relationship in clinical tissues. Both Loc490 and QKI were expressed at significantly lower levels in GC tissues and lymph node metastasis tissues than in adjacent normal tissues. These results suggested that the downregulation of Loc490 and QKI promotes the carcinogenesis and metastasis of GC. The positive correlation between Loc490 and QKI levels in tumor tissues further suggested that there could be a relationship between Loc490 and QKI.
We then analyzed the clinical significance of Loc490 in GC, and found that low Loc490 expression was associated with vein/nerve invasion, lymph node metastasis and a poor prognosis in GC patients. To clarify the effects of Loc490 on the malignant behavior of GC cells, we measured Loc490 expression in various GC cell lines. We found that Loc490 expression was lower in GC cell lines than in normal gastric epithelial cells. Since Loc490 expression was the lowest in SGC-7901 cells and highest in AGS cells, we used these cell lines to construct the Loc490 overexpression and interference cell models, respectively. The proliferation and metastasis abilities of SGC-7901 cells were significantly reduced after Loc490 overexpression, while the proliferation and metastasis abilities of AGS cells were significantly elevated after Loc490 silencing. Thus, reducing the expression of Loc490 promoted the proliferation and metastasis of GC cells in vitro.
To determine the impact of Loc490 on QKI and its downstream target genes, we detected the mRNA and protein levels of QKI and EMT-associated molecules in Loc490-overexpressing and -knockdown cells. N-cadherin, E-cadherin, MMP-9 and Vimentin are generally considered to be EMT-related proteins, and their expression is known to be associated with QKI expression [27–29]. Our results demonstrated that Loc490 significantly enhanced QKI protein expression and inhibited EMT-related protein expression. However, Loc490 did not significantly modify QKI mRNA levels, suggesting that Loc490 may alter the stability of QKI post-translationally, thus inducing QKI protein accumulation and downstream target gene expression. In addition, an RNA immunoprecipitation assay confirmed that Loc490 could bind to QKI protein. To better understand the upstream/downstream relationship between Loc490 and QKI, we used siRNA to reduce QKI expression in Loc490-overexpressing cells. We found that siQKI significantly antagonized the antitumor effects of Loc490 overexpression both in vitro and in vivo. Thus, Loc490 inhibits GC progression through its downstream effects on QKI. We also assessed potential binding sites between Loc490 and QKI, and found that mutating nucleotides 760-778 and 860-869 on Loc490 significantly reduced its ability to bind to QKI.
In conclusion, we performed transcriptome microarray analyses to detect differentially expressed lncRNAs in GC samples, normal stomach tissues and lymph node metastases. We found that the downregulation of lncRNA LOC101927490 was associated with increased TNM stages, enhanced lymph node metastasis and reduced overall survival in GC patients. Our in vitro experiments suggested that Loc490 post-translationally modifies QKI. In future studies, we will use post-translational modification proteomics to explore potential post-translational modification sites on QKI and to clarify the effects of Loc490 expression on them. Moreover, our in vivo studies indicated that Loc490 inhibited the subcutaneous tumorigenesis of GC cells in nude mice in a QKI-dependent manner (Figure 5F). Further studies are needed to explore this mechanism in vivo and to confirm the suitability of Loc490 as a new target for the clinical diagnosis and treatment of GC. We plan to investigate the effects of small molecules such as small-activating RNAs [30–31] on GC cells, to determine whether inducing Loc490 could antagonize the malignant behavior of these cells and delay or even prevent the clinical progression of GC.
Materials and Methods
Cell culture, antibodies, plasmids and transfection
The human embryonic kidney cell line 293T, the normal gastric epithelial cell line GES-1 and the GC cell lines AGS, SGC-7901, BGC-823 and MGC-803 were obtained from the Cancer Research Institute of Central South University. Dulbecco’s modified Eagle’s medium/F12 (Hyclone) was used to culture the AGS cells. RPMI-1640 medium (Gibco) was used to culture the GES-1, SGC-7901, BGC-823 and MGC-803 cells. All the media were supplemented with 10% fetal bovine serum (FBS). The cell lines were negative for mycoplasma contamination. All cell lines were passaged less than 10 times after their initial revival from frozen stocks, and were authenticated via short tandem repeat profiling prior to use.
The primary antibodies against E-cadherin (BS90443) and N-cadherin (BS72312), along with the goat anti-rabbit IgG (H+L) horseradish peroxidase antibody (BS10003), were purchased from Bioworld. Antibodies against Vimentin (EPR3776), MMP-9 (EP1255Y) and QKI (EPR7306) were obtained from Abcam. Antibodies against α-Tubulin (T9026) were purchased from Sigma.
The lentiviral overexpression vector containing full-length Loc490 cDNA in a pLVX-EF1a-IRES-Puro plasmid (632186) was purchased from Clontech, along with the control vectors. The lentiviral short-hairpin RNA clones targeting Loc490 (STK300-10) and the non-targeting control vector (LP105-100) were purchased from GeneCopoeia. The Loc490 mutant #1 and #2 vectors were designed by and purchased from OE Biotech. The plasmid vectors were verified through sequencing.
We generated stable overexpression and knockdown cell lines by using Lipofectamine 2000 (Thermo Scientific, 11668027) to transfect 293T cells with pCMV-VSV-G (#8454), pMDLg-Prre (#12251) and pRSV-Rev (#12253) (Addgene) vectors containing the full-length Loc490, short-hairpin RNA targeting Loc490 and the corresponding controls, respectively. Viral supernatant fractions were collected 48 hours after transfection, and were filtered through a 0.45-μm filter (Millipore) before being used to infect GC cell lines three times over 24 hours. After three days, the cells were incubated in medium containing 1 μg/mL puromycin (Sigma) for one week.
Study cohort and tissue samples
Between January 2014 and December 2015 at Xiangya Hospital, Central South University, 83 patients diagnosed with GC were randomly selected as cohort participants at random intervals. Among patients diagnosed with primary GC, those who received neoadjuvant chemotherapy treatment prior to surgery were excluded from the study. Every three months, each patient’s information was updated through a follow-up scheme or telephone visit. In total, 28 GC tissues and 28 corresponding adjacent normal tissues that were ≥ 5 cm from the cancer tissues were resected, placed in 1.5-mL Eppendorf tubes and stored at -80°C. The ethics committee of Xiangya Hospital, Central South University approved this study.
Agilent Human LncRNA chip
An Agilent Human LncRNA gene chip (4*180K, Design ID: 076500) was used to detect the lncRNA levels in 15 clinical samples (5 normal tissues adjacent to GC, 5 GC tissues and 5 metastatic lymph node tissues). Total RNA was quantified on a NanoDrop ND-2000 (Thermo Scientific), and the RNA integrity was detected on an Agilent Bioanalyzer 2100 (Agilent Technologies). The marking of samples, hybridization of chips and elution were performed in accordance with standard procedures. Feature Extraction (version 10.7.1.1, Agilent Technologies) and Genespring (version 13.1, Agilent Technologies) were used to process the data and screen for differentially expressed genes (fold change > 2.0 and p value < 0.05). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to analyze the differentially expressed genes.
Total RNA from cells or tissues was extracted with 1 mL of RNAiso plus (Takara). Then, cDNAs were synthesized with SuperScript II (Takara). A mixture containing 10 μL of All-in-One qPCR reagent (GeneCopoeia), 5 μL of cDNA and 5 μL of primers (forward and reverse, Table 2) was used to perform fluorescence qRT-PCR. The PCR cycling conditions were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. GAPDH was used as an internal reference gene, and relative mRNA expression was analyzed using the 2-ΔΔCT method.
Table 2. RT-PCR primer sequence.
Western blot analysis
Cells were lysed in 1 mL of cell lysis buffer (Beyotime Biotechnology). The cell lysate was mixed with 5x loading buffer (Beyotime Biotechnology) and the mixture was heated to 100°C. Then, 50 μg of total protein was separated on a 10% sodium dodecyl sulfate polyacrylamide gel. The protein levels of QKI, E-cadherin, Vimentin, N-cadherin, MMP-9 and α-Tubulin (the internal control) were analyzed using standard techniques with primary antibodies diluted 1:1000. The relative protein levels were calculated based on the strip grey values using ImageJ software.
Cell proliferation assay and plate colony formation assay
Cells were seeded into 96-well plates at a density of 1×103 cells/well in RPMI-1640 medium (100 μL). After a 24-hour incubation, the cells were transfected with plasmids or short-hairpin RNAs and incubated for another 24 to 72 hours. Cell viability was determined on a VERSAmax microplate reader (Molecular Devices) using the MTS method in accordance with the manual of the CellTiter 96 Aqueous One Solution Cell Proliferation assay (Promega). The cell survival rate was expressed as A/B × 100, where A is the absorbance value from the experimental cells and B is that from the control (untreated) cells.
For the plate colony formation assay, cells (2×103/mL/well) were seeded into six-well plates and cultured in RPMI-1640 medium supplemented with 10% FBS. Colonies were fixed with methanol, stained with crystal violet and scored using ImageJ software.
Transwell migration and invasion assays
For the Transwell invasion assays, 50 mg/L Matrigel (BD Biosciences) was used to cover the Transwell invasion chamber (Corning). Cells (5×105) were mixed with 100 μL of RPMI-1640 medium containing 2% FBS and seeded into the upper chamber of the Transwell invasion system, while 600 μL of RPMI-1640 medium containing 10% FBS was added to the lower chamber. The chamber was then placed in an incubator for 24 hours. Subsequently, the upper chamber was removed and the medium was discarded. A 10% methanol solution was used for cell fixation and a 0.1% crystal violet solution was used for staining.
The Transwell migration assays were carried out in a Transwell invasion chamber without the covering of 50 mg/L Matrigel. Cells (2×105) were mixed with 100 μL of RPMI-1640 medium containing 2% FBS and seeded into the upper chamber of the Transwell migration system. The other steps were the same as above.
Cells were resuspended in phosphate-buffered saline and treated with 1 mL of freshly prepared ice-cold lysis buffer on ice for 20 min. Pellets were extracted via centrifugation at 14,000 rpm for 10 min. Then, 2 μg of an anti-QKI antibody and 40 μL of protein A/G beads were added to create a protein suspension, which was incubated for 12 hours at 4°C with gentle rotation. The beads were pelleted through centrifugation at 2,500 rpm for 30 seconds; then, the supernatant was removed and the beads were resuspended in 500 mL of RNA immunoprecipitation buffer. This was repeated for a total of three RNA immunoprecipitation buffer washes, followed by a wash in phosphate-buffered saline. Then, 1 mL of RNAiso was added to extract the total RNA. The remaining processes were the same as those for qRT-PCR.
In vivo xenograft mouse model
Nude mice were inoculated subcutaneously with SGC-7901 cells in three groups: Vector + siControl, Loc490 + siControl, and Loc490 + siQKI (5x106 cells and n = 5/group). Seven days after the inoculation, the tumor length (L) and width (W) were measured with a caliper. Tumor volumes were calculated with the formula L × W2 × π/6. All measurements were compared using an unpaired Student’s t-test.
Data were processed with the Statistical Package for the Social Sciences 19.0 (SPSS 19.0, Inc., Chicago, IL, USA). Results are expressed as the mean ± standard deviation (SD). Two-tailed Student’s t-tests were used for comparisons of two groups, while one-way analysis of variance was used for comparisons of three or more groups. A p value < 0.05 was considered statistically significant. *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively.
LB and ZYH conceived and designed the study. HZX performed the experiments and wrote the paper. CL provided the gastric cancer sample. LB, ZYH and DZJ reviewed and edited the manuscript. All authors read and approved the manuscript.
We would like to acknowledge Mrs. Elizabeth Spiegler in the Department of Aging Editing Service for her English revision on this manuscript.
Conflicts of Interest
The authors do not have any actual or potential conflict of interest related to this study.
This work was supported by Project 2020JJ5898 supported by Hunan Province Science Foundation for Youths which supports the Xiangya Hospital (He ZX).
- 1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115–32. https://doi.org/10.3322/caac.21338 [PubMed]
- 2. Dong J, Wang R, Ren G, Li X, Wang J, Sun Y, Liang J, Nie Y, Wu K, Feng B, Shang Y, Fan D. HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin Cancer Res. 2017; 23:3461–73. https://doi.org/10.1158/1078-0432.CCR-16-2180 [PubMed]
- 3. Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei ZW, Zhu JT, Yu J, Chen W, He Y, Schwarz RE, Brekken RA, Awasthi N, Zhang CH. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene. 2017; 36:5122–33. https://doi.org/10.1038/onc.2017.108 [PubMed]
- 4. He Z, Dong W, Li Q, Qin C, Li Y. Sauchinone prevents TGF-β-induced EMT and metastasis in gastric cancer cells. Biomed Pharmacother. 2018; 101:355–61. https://doi.org/10.1016/j.biopha.2018.02.121 [PubMed]
- 5. Carlson HL, Quinn JJ, Yang YW, Thornburg CK, Chang HY, Stadler HS. LncRNA-HIT functions as an epigenetic regulator of chondrogenesis through its recruitment of p100/CBP complexes. PLoS Genet. 2015; 11:e1005680. https://doi.org/10.1371/journal.pgen.1005680 [PubMed]
- 6. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015; 21:1253–61. https://doi.org/10.1038/nm.3981 [PubMed]
- 7. Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y, Jiang X. LncRNA-ATB: An indispensable cancer-related long noncoding RNA. Cell Prolif. 2017; 50:e12381. https://doi.org/10.1111/cpr.12381 [PubMed]
- 8. Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018; 107:2620–29. https://doi.org/10.1016/j.ijbiomac.2017.10.154 [PubMed]
- 9. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, De W, Wang KM, Wang ZX. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014; 13:92. https://doi.org/10.1186/1476-4598-13-92 [PubMed]
- 10. Yan J, Dang Y, Liu S, Zhang Y, Zhang G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016. [Epub ahead of print]. https://doi.org/10.1007/s13277-016-5448-5 [PubMed]
- 11. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5:2318–29. https://doi.org/10.18632/oncotarget.1913 [PubMed]
- 12. Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012; 279:3159–65. https://doi.org/10.1111/j.1742-4658.2012.08694.x [PubMed]
- 13. Zhou X, Ye F, Yin C, Zhuang Y, Yue G, Zhang G. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer. Cell Physiol Biochem. 2015; 36:1440–52. https://doi.org/10.1159/000430309 [PubMed]
- 14. Chen D, Liu L, Wang K, Yu H, Wang Y, Liu J, Guo Y, Zhang H. The role of MALAT-1 in the invasion and metastasis of gastric cancer. Scand J Gastroenterol. 2017; 52:790–96. https://doi.org/10.1080/00365521.2017.1280531 [PubMed]
- 15. Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2017; 21:3850–56. [PubMed]
- 16. Zhou X, Ji G, Ke X, Gu H, Jin W, Zhang G. MiR-141 inhibits gastric cancer proliferation by interacting with long noncoding RNA MEG3 and down-regulating E2F3 expression. Dig Dis Sci. 2015; 60:3271–82. https://doi.org/10.1007/s10620-015-3782-x [PubMed]
- 17. Suiko T, Kobayashi K, Aono K, Kawashima T, Inoue K, Ku L, Feng Y, Koike C. Expression of quaking RNA-binding protein in the adult and developing mouse retina. PLoS One. 2016; 11:e0156033. https://doi.org/10.1371/journal.pone.0156033 [PubMed]
- 18. Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H, Hui J. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 2014; 10:e1004289. https://doi.org/10.1371/journal.pgen.1004289 [PubMed]
- 19. Zhao Y, Zhang G, Wei M, Lu X, Fu H, Feng F, Wang S, Lu W, Wu N, Lu Z, Yuan J. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. Cancer Biol Ther. 2014; 15:108–18. https://doi.org/10.4161/cbt.26722 [PubMed]
- 20. He B, Gao SQ, Huang LD, Huang YH, Zhang QY, Zhou MT, Shi HQ, Song QT, Shan YF. MicroRNA-155 promotes the proliferation and invasion abilities of colon cancer cells by targeting quaking. Mol Med Rep. 2015; 11:2355–59. https://doi.org/10.3892/mmr.2014.2994 [PubMed]
- 21. Lu W, Feng F, Xu J, Lu X, Wang S, Wang L, Lu H, Wei M, Yang G, Wang L, Lu Z, Liu Y, Lei X. QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2. Cancer Biol Ther. 2014; 15:1174–84. https://doi.org/10.4161/cbt.29502 [PubMed]
- 22. Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, et al. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015; 6:24599–610. https://doi.org/10.18632/oncotarget.5248 [PubMed]
- 23. Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu H, Lu X, Wei M, Sun J, Zhao Q, Dong G, Lu Z. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochem Biophys Res Commun. 2012; 422:187–93. https://doi.org/10.1016/j.bbrc.2012.04.138 [PubMed]
- 24. Dong Y, Yoshitomi T, Hu JF, Cui J. Long noncoding RNAs coordinate functions between mitochondria and the nucleus. Epigenetics Chromatin. 2017; 10:41. https://doi.org/10.1186/s13072-017-0149-x [PubMed]
- 25. Gu Y, Chen T, Li G, Yu X, Lu Y, Wang H, Teng L. LncRNAs: emerging biomarkers in gastric cancer. Future Oncol. 2015; 11:2427–41. https://doi.org/10.2217/fon.15.175 [PubMed]
- 26. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni SJ, Dong L, Yang Y, Lin W, Xu Q, Huang D, et al. A positive feedback loop of lncRNA- PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res. 2017; 23:2071–80. https://doi.org/10.1158/1078-0432.CCR-16-0742 [PubMed]
- 27. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015; 160:1125–34. https://doi.org/10.1016/j.cell.2015.02.014 [PubMed]
- 28. Han J, Meng J, Chen S, Wang X, Yin S, Zhang Q, Liu H, Qin R, Li Z, Zhong W, Zhang C, Zhang H, Tang Y, et al. YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma. Cancer Res. 2019; 79:1451–64. https://doi.org/10.1158/0008-5472.CAN-18-2238 [PubMed]
- 29. Pillman KA, Phillips CA, Roslan S, Toubia J, Dredge BK, Bert AG, Lumb R, Neumann DP, Li X, Conn SJ, Liu D, Bracken CP, Lawrence DM, et al. miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein quaking. EMBO J. 2018; 37:e99016. https://doi.org/10.15252/embj.201899016 [PubMed]
Connelly CM, Moon MH, Schneekloth JS
Jr. The Emerging Role of RNA as a Therapeutic Target for Small Molecules. Cell Chem Biol. 2016; 23:1077–1090. https://doi.org/10.1016/j.chembiol.2016.05.021 [PubMed]
- 31. Wang B, Sun J, Shi J, Guo Q, Tong X, Zhang J, Hu N, Hu Y. Small-activating RNA can change nucleosome positioning in human fibroblasts. J Biomol Screen. 2016; 21:634–42. https://doi.org/10.1177/1087057116637562 [PubMed]